News stories about Boston Scientific (NYSE:BSX) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Boston Scientific earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave news headlines about the medical equipment provider an impact score of 46.3888731879694 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:
- Boston Scientific (BSX) Given Buy Rating at Royal Bank of Canada (americanbankingnews.com)
- Boston Scientific (BSX) Coverage Initiated by Analysts at Evercore ISI (americanbankingnews.com)
- More Controversy Over Major Cardiology Clinical Trial (finance.yahoo.com)
- Boston Scientific (BSX) Stock Rating Lowered by Zacks Investment Research (americanbankingnews.com)
- Have Sufficient Potential Left To Grow? Boston Scientific Corporation (BSX), Delta Air Lines, Inc. (DAL) (nmsunews.com)
BSX has been the topic of a number of recent analyst reports. Morgan Stanley boosted their price objective on Boston Scientific from $30.00 to $33.00 and gave the stock an “overweight” rating in a research note on Monday, March 19th. BMO Capital Markets reissued a “buy” rating and issued a $32.00 price objective on shares of Boston Scientific in a research note on Tuesday, December 12th. SunTrust Banks set a $33.00 price objective on Boston Scientific and gave the stock a “buy” rating in a research note on Monday, December 4th. Piper Jaffray initiated coverage on Boston Scientific in a research note on Friday, February 23rd. They issued an “overweight” rating and a $31.00 price objective on the stock. Finally, Needham & Company LLC reissued a “buy” rating and issued a $32.00 price objective on shares of Boston Scientific in a research note on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $31.32.
Boston Scientific (NYSE:BSX) last released its earnings results on Thursday, February 1st. The medical equipment provider reported $0.34 earnings per share for the quarter, meeting the consensus estimate of $0.34. Boston Scientific had a return on equity of 24.27% and a net margin of 1.15%. The firm had revenue of $2.41 billion for the quarter, compared to analyst estimates of $2.39 billion. During the same quarter in the prior year, the firm posted $0.30 earnings per share. The company’s quarterly revenue was up 9.9% on a year-over-year basis. research analysts anticipate that Boston Scientific will post 1.37 EPS for the current fiscal year.
In other Boston Scientific news, CFO Daniel J. Brennan sold 60,209 shares of the stock in a transaction dated Monday, March 19th. The stock was sold at an average price of $27.87, for a total value of $1,678,024.83. Following the transaction, the chief financial officer now owns 299,644 shares of the company’s stock, valued at $8,351,078.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Kevin J. Ballinger sold 42,803 shares of the stock in a transaction dated Wednesday, March 14th. The stock was sold at an average price of $28.32, for a total value of $1,212,180.96. The disclosure for this sale can be found here. Insiders sold 247,818 shares of company stock worth $6,743,788 in the last three months. Insiders own 0.74% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Boston Scientific (NYSE:BSX) Share Price” was reported by BBNS and is the sole property of of BBNS. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://baseballnewssource.com/2018/04/02/boston-scientific-bsx-given-daily-news-sentiment-score-of-0-15/2003720.html.
Boston Scientific Company Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.